Streetbeat News

PBM

Psyence Biomedical Ltd. Common Shares

https://www.psyence.com

Industry

Biotechnology

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Open

0.06

Mkt cap

3.2M

Volume

3.5M

High

0.06

P/E Ratio

-0.01

52-wk high

14.55

Low

0.05

Div yield

N/A

52-wk low

0.05

Psyence Biomedical has agreed to acquire an 11.13% stake in PsyLabs from Psyence Group for $1.1 million, issuing shares at $0.55 each.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 11:33 am

Psyence Biomedical Ltd. (NASDAQ:PBM) is advancing its psychedelic-based mental health solutions with a Phase IIb trial in Australia and the acquisition of Clairvoyant. The company is also partnering with Optimi Health (OTC:OPTHF) for psilocybin supply, aiming for significant data readouts in 2025.

Portfolio Pulse from Juan Spínelli

September 16, 2024 | 5:42 pm

Psyence Biomedical, a NASDAQ-listed associate of Psyence Group, has initiated its first trial site in Australia for a Phase IIb study. The study focuses on using nature-derived psilocybin as a potential treatment for adjustment disorder in palliative care.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:36 pm

Exicure, Inc. (NASDAQ:XCUR) shares surged over 49% in pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Other notable pre-market movers include NuCana plc (NASDAQ:NCNA) with a 94.4% gain due to positive Phase 2 study data, and Dermata Therapeutics, Inc. (NASDAQ:DRMA) rising 73.4%. On the downside, Rafael Holdings, Inc. (NYSE:RFL) fell 40.1% after previous gains.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 10:07 am

Psyence Biomedical has received a delisting determination from Nasdaq due to non-compliance. The company has not regained compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 8:31 pm

Psyence Biomedical Ltd. (NASDAQ:PBM) has launched its first clinical trial site in Australia for a Phase IIb study on psilocybin as a treatment for Adjustment Disorder in palliative care patients. This marks a significant step in advancing psychedelic-based treatments, with patient screening starting immediately and data expected by 2025.

Portfolio Pulse from Juan Spínelli

September 09, 2024 | 10:02 pm

Psyence Biomedical's shares rose following the announcement of a conditional binding term sheet to acquire Clairvoyant Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:39 am

Psyence Biomedical has entered a conditional binding term sheet to acquire Clairvoyant Therapeutics. The acquisition involves issuing $500,000 in common shares and potential additional payments based on milestone achievements. Psyence will also provide up to $1.80 million to settle Clairvoyant's liabilities.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:32 am

U.S. stocks showed mixed performance with the Nasdaq Composite gaining slightly. Dollar Tree shares fell significantly after disappointing earnings, while Faraday Future, Atara Biotherapeutics, and WiSA Technologies saw substantial gains. Athira Pharma and Oragenics experienced sharp declines.

Portfolio Pulse from Avi Kapoor

September 04, 2024 | 5:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.